Aqst stock forecast the AQST stock forecast scenario for Q2

The AQST stock forecast scenario for Q2 2024 aligns with analyst models projecting a 15% YoY revenue increase, driven by enhanced licensing deals. Traders see $3.20 as the next test level. To get a sense of who is truly in control of Aquestive Therapeutics, Inc. ( NASDAQ:AQST ), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are institutions with 48% ownership. Put another way, the group faces the maximum upside potential (or downside risk). The Anaphylm Sublingual Film is being developed as a non-invasive oral epinephrine product candidate. Based on recent market activity, AQST stock forecast shows cautious optimism, with shares trading around the $2.77 level, up nearly 5% over the past week. Analysts note growing interest in Aquestive Therapeutics’ late-stage pipeline, particularly for CNS disorders, which could push revenue growth in